INTRODUCTION

Eptinezumab (brand name Vyepti) is a fully-humanized IgG1 monoclonal antibody that binds to both alpha and beta forms of the human calcitonin gene-related peptide (CGRP). Eptinezumab is used for the preventive treatment of migraine in adults.

This plasmid is designed for expressing Eptinezumab in yeast expression system (Pichia pastoris).

PRODUCT INFORMATION

Item No.: PPBD-72
Shipping: Lyophilized plasmid, or liquid plasmid, or plasmids on filter paper
Storage: -20 °C or 4°C according to instruction
Plasmid Backbone: Expression plasmid, flexible options for promoter and selection marker, custom available
Quality Control: Sequencing validation

DRUG INFORMATION

Generic Name: Eptinezumab
Brand Name(s): Vyepti
Classification: Monoclonal antibody (mAb)
Target: calcitonin related polypeptide alpha (CALCA), CT, KC, PCT, CGRP, CALC1, CGRP1, CGRP-I, CGRP-alpha
Action Type: Inhibitor
Amino Acid Sequence: Identical to DB14040

PROTOCOL FOR PLASMID RECOVERY FROM FILTER PAPER

REFERENCE

[1] Pellesi L, Guerzoni S, Pini LA. Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date. Clin Pharmacol Drug Dev. 2017 Nov;6(6):534-547.

[2] Benemei S, Cortese F, Labastida-Ramírez A, Marchese F, Pellesi L, Romoli M, Vollesen AL, Lampl C, Ashina M; School of Advanced Studies of the European Headache Federation (EHF-SAS). Triptans and CGRP blockade - impact on the cranial vasculature. J Headache Pain. 2017 Oct 10;18(1):103.

Contact Us